FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.
The FDA approved Roivant’s dermatomyositis drug brepocitinib on Wednesday, the first major regulatory nod that could usher in a multibillion revenue stream for the hub-and-spoke …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned…
The FDA has approved Lisraya for the treatment of dermatomyositis in adults, the agency announced in a press release. The…
The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune…
Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the…
Treatment with once-daily brepocitinib improved skin disease, muscle and physical function measures for adults with…
DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according…
FDA approves Roivant therapy for rare autoimmune disease
